{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:57:18Z","timestamp":1792155438160,"version":"4.4.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Effective bladder-preserving therapeutic options are needed for patients with bacillus Calmette-Gu\u00e9rin unresponsive non\u2013muscle-invasive bladder cancer. Nadofaragene firadenovec-vncg (Adstiladrin<jats:sup>\u00ae<\/jats:sup>) was approved by the US Food and Drug Administration as the first gene therapy in urology and the first intravesical gene therapy indicated for the treatment of adult patients with high-risk bacillus Calmette-Gu\u00e9rin\u2013unresponsive non\u2013muscle-invasive bladder cancer with carcinoma <jats:italic>in situ<\/jats:italic> with or without papillary tumors. The proposed mechanism of action underlying nadofaragene firadenovec efficacy is likely due to the pleiotropic nature of interferon-\u03b1 and its direct and indirect antitumor activities. Direct activities include cell death and the mediation of an antiangiogenic effect, and indirect activities are those initiated through immunomodulation of the innate and adaptive immune responses. The sustained expression of interferon-\u03b1 that results from this treatment modality contributes to a durable response. This review provides insight into potential mechanisms of action underlying nadofaragene firadenovec efficacy.<\/jats:p>","DOI":"10.3389\/fonc.2024.1359725","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:12:32Z","timestamp":1710501152000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Mechanism of action of nadofaragene firadenovec-vncg"],"prefix":"10.3389","volume":"14","author":[{"given":"Vikram M.","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Meeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f8rn S.","family":"Jakobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grannum R.","family":"Sant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R.","family":"Konety","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European association of urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC guidelines panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"B4","volume-title":"Bladder cancer","year":"2023"},{"key":"B5","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/cncr.30392","article-title":"Non-muscle-invasive bladder cancer: Intravesical treatments beyond Bacille Calmette-Gu\u00e9rin","volume":"123","author":"Packiam","year":"2017","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00262-019-02443-4","article-title":"Mechanisms of immune evasion in bladder cancer","volume":"69","author":"Crispen","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01270","article-title":"Immune responses in bladder cancer-role of immune cell populations, prognostic factors and therapeutic implications","volume":"9","author":"Joseph","year":"2019","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7248","DOI":"10.3390\/ijms22147248","article-title":"Tumor escape phenotype in bladder cancer is associated with loss of HLA Class I expression, T-cell exclusion and stromal changes","volume":"22","author":"Gil-Julio","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ucl.2019.09.011","article-title":"Intravesical gene therapy","volume":"47","author":"Narayan","year":"2020","journal-title":"Urol Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-021-03666-w","article-title":"BCG-unresponsive high-grade non-muscle invasive bladder cancer: what does the practicing urologist need to know","volume":"39","author":"Lebacle","year":"2021","journal-title":"World J Urol"},{"key":"B12","volume-title":"BCG-Unresponsive nonmuscle invasive bladder cancer: developing drugs and biologics for treatment: guidance for industry","year":"2018"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: An overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/181987","article-title":"Bladder cancer immunotherapy: BCG and beyond","volume":"2012","author":"Askeland","year":"2012","journal-title":"Adv Urol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"194","DOI":"10.20892\/j.issn.2095-3941.2016.0020","article-title":"Nonmuscle invasive bladder cancer: a primer on immunotherapy","volume":"13","author":"Maruf","year":"2016","journal-title":"Cancer Biol Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11912-022-01350-9","article-title":"Novel therapies for high-risk non-muscle invasive bladder cancer","volume":"25","author":"Al Hussein Al Awamlh","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B17","volume-title":"NCCN Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 3.2023","year":"2023"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2023.06.018","article-title":"Sequential intravesical gemcitabine\/docetaxel provides a durable remission in recurrent high-risk NMIBC following BCG therapy","volume":"41","author":"Yim","year":"2023","journal-title":"Urol Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2017.00260","article-title":"Intravesical gemcitabine versus intravesical bacillus calmette-guerin for the treatment of non-muscle invasive bladder cancer: an evaluation of efficacy and toxicity","volume":"7","author":"Prasanna","year":"2017","journal-title":"Front Oncol"},{"key":"B22","volume-title":"KEYTRUDA 50 mg powder for concentrate for solution for infusion","year":"2020"},{"key":"B23","volume-title":"ADSTILADRIN","year":"2022"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3906\/sag-2005-327","article-title":"Immune gene therapy of cancer","volume":"50","author":"Akbulut","year":"2020","journal-title":"Turk J Med Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/hum.2013.2527","article-title":"Adenovirus: the first effective in vivo gene delivery vector","volume":"25","author":"Crystal","year":"2014","journal-title":"Hum Gene Ther"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1260498","article-title":"Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval","volume":"14","author":"Martini","year":"2023","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.02.015","article-title":"Sustained intravesical interferon protein exposure is achieved using an adenoviral-mediated gene delivery system: a study in rats evaluating dosing regimens","volume":"66","author":"Connor","year":"2005","journal-title":"Urology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.03.030","article-title":"Phase I trial of intravesical recombinant adenovirus mediated interferon-\u03b12b formulated in Syn3 for Bacillus Calmette-Gu\u00e9rin failures in nonmuscle invasive bladder cancer","volume":"190","author":"Dinney","year":"2013","journal-title":"J Urol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700488","article-title":"Syn3 provides high levels of intravesical adenoviral-mediated gene transfer for gene therapy of genetically altered urothelium and superficial bladder cancer","volume":"9","author":"Yamashita","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.05.027","article-title":"Intravesical Ad-IFNalpha causes marked regression of human bladder cancer growing orthotopically in nude mice and overcomes resistance to IFN-alpha protein","volume":"10","author":"Benedict","year":"2004","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cgt.7700865","article-title":"Efficacy of a single intravesical treatment with Ad-IFN\/Syn 3 is dependent on dose and urine IFN concentration obtained: implications for clinical investigation","volume":"13","author":"Tao","year":"2006","journal-title":"Cancer Gene Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.11.006","article-title":"Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance","volume":"23","author":"Green","year":"2021","journal-title":"Mol Ther Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2011.26","article-title":"Direct cytotoxicity produced by adenoviral-mediated interferon \u03b1 gene transfer in interferon-resistant cancer cells involves ER stress and caspase 4 activation","volume":"18","author":"Yang","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.6.4088","article-title":"Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells","volume":"6","author":"Papageorgiou","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B35","article-title":"Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration","volume":"58","author":"Dinney","year":"1998","journal-title":"Cancer Res"},{"key":"B36","article-title":"Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule","volume":"5","author":"Slaton","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.19531","article-title":"Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy","volume":"8","author":"Medrano","year":"2017","journal-title":"Oncotarget"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urol Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.02.010","article-title":"Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer","volume":"32","author":"Lamm","year":"2014","journal-title":"Urol Oncol"},{"key":"B40","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"J Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.06.007","article-title":"Enhancement of intravesical delivery with Syn3 potentiates interferon-\u03b12b gene therapy for superficial bladder cancer","volume":"18","author":"Nagabhushan","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-018-2553-7","article-title":"The development of interferon-based gene therapy for BCG unresponsive bladder cancer: from bench to bedside","volume":"37","author":"Duplisea","year":"2019","journal-title":"World J Urol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.72.3064","article-title":"Intravesical rAd-IFN\u03b1\/syn3 for patients with high-grade, Bacillus Calmette-Guerin-refractory or relapsed non-muscle-invasive bladder cancer: A phase II randomized study","volume":"35","author":"Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.12.009","article-title":"Antiadenovirus antibodies predict response durability to nadofaragene firadenovec therapy in BCG-unresponsive non-muscle-invasive bladder cancer: Secondary analysis of a phase 3 clinical trial","volume":"81","author":"Mitra","year":"2022","journal-title":"Eur Urol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0804269","article-title":"Antiviral antibodies target adenovirus to phagolysosomes and amplify the innate immune response","volume":"182","author":"Zaiss","year":"2009","journal-title":"J Immunol"},{"key":"B46","unstructured":"Ferring announces full availability of ADSTILADRIN\u00ae (nadofaragene firadenovec-vncg) in the U.S2024"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00526","article-title":"The interactions between cancer stem cells and the innate interferon signaling pathway","volume":"11","author":"Martin-Hijano","year":"2020","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-022-00415-y","article-title":"Direct and indirect effects of IFN-\u03b12b in Malignancy treatment: not only an archer but also an arrow","volume":"10","author":"Xiong","year":"2022","journal-title":"biomark Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-04-1909","article-title":"Role of tumor necrosis factor-related apoptosis-inducing ligand in interferon-induced apoptosis in human bladder cancer cells","volume":"64","author":"Papageorgiou","year":"2004","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/cgt.2014.1","article-title":"Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFN\u03b1\/Syn3 treatment in a phase l study","volume":"21","author":"Benedict","year":"2014","journal-title":"Cancer Gene Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/95.6.437","article-title":"Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis","volume":"95","author":"von Marschall","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00251-010-0494-4","article-title":"Frequent loss of heterozygosity in the \u03b22-microglobulin region of chromosome 15 in primary human tumors","volume":"63","author":"Maleno","year":"2011","journal-title":"Immunogenetics"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1359725\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T11:12:37Z","timestamp":1710501157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1359725\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":52,"alternative-id":["10.3389\/fonc.2024.1359725"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1359725","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"article-number":"1359725"}}